绥美凯主治什么呢？

(Inbec) has been approved in more than 100 countries and recommended by many authoritative academic institutions in Europe and the United States as a first-line treatment drug for newly treated AIDS patients. From the comparison with patients who failed the first-line treatment of the other two integrase inhibitors RAL (Ascent) and EVG (elvitegravir), Inbec (Inbec) has significantly fewer resistance mutation sites than the other two drugs, making it less likely to develop resistance.

In 2018, GlaxoSmithKline (GSK) announced that its joint venture ViiV Healthcare’s single-pill compound preparation Inbec, which is based on the new generation integrase inhibitor Tevicavir (dolutegravir) and is used to treat HIV, was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China.

Inbec is a treatment plan based on DTG, an integrase inhibitor, as the core drug, coupled with two backbone drugs, abacavir and lamivudine, and made into a single-tablet treatment for promotion, which has made great progress in the HAART treatment of core drugs.

Trimax is suitable for adults and adolescents over 12 years old and weighing no less than 40kg. Since the ingredients in Trimax may cause hypersensitivity reactions, patients should be screened for HLA-B*5701 alleles before starting treatment with abacavir-containing products, regardless of race.

The recommended dosage of SuimeiKai is one tablet, once daily. Adults or adolescents whose weight is less than 40kg should not be given Trimax, because Trimax is a fixed-dose tablet and the dose cannot be reduced. Reducing the dose without authorization may result in the inefficiency of the drug.

(Inbec) clinical data are limited, and the most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacalongvir/lamivudine are nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).